A major challenge in combating significant human pathogens is the inherent variation of viruses that can evolve to evade the host immune response and antiviral treatment strategies. Our research proposes an interdisciplinary appro...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
LOFlu
Controlling Influenza A Virus Liquid Organelles
3M€
Cerrado
AVFLU
Interactions between avian and influenza virus proteins
100K€
Cerrado
UNIVERSITEIT UTRECHT
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
183K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
A major challenge in combating significant human pathogens is the inherent variation of viruses that can evolve to evade the host immune response and antiviral treatment strategies. Our research proposes an interdisciplinary approach to identify novel antiviral targets by interrogating the host cell biology of infection by influenza A virus (IAV), human immunodeficiency virus (HIV) and hepatitis C virus (HCV) using high-throughput RNA interference (RNAi) technologies. More specifically, we propose to understand the dependency of these enveloped viruses on the host endoplasmic reticulum (ER) machinery for virus replication and propagation and how this increased virus burden activates host-ER stress, including the unfolded protein response (UPR). The UPR is implicated in inflammatory signaling and we will further investigate whether these viruses can modulate host immune responses via this pathway. In summary, we have proposed a hypothesis-driven RNAi screen to generate an overview of common host-cell factors exploited by diverse viruses during infection as well as extensive biochemical and functional validation of any sites of conserved virus-protein interactions. Therefore, this work aims to identify novel candidates for further translational research and development as improved, broad-spectrum antiviral treatments to combat infection and associated pathogenesis.